Rational decisions in managing sore throat: evaluation of a rapid test

Antibiotic use in sore throat management remains high despite guidelines. Clinical signs like dysphagia and inflamed tonsils often influence prescriptions. Broad-spectrum antibiotics are frequently chosen. Prior research has shown variable accuracy in clinical assessments. No prior work had resolved the effectiveness of rapid tests in altering prescribing. This gap motivated the evaluation of an enzyme immunoassay. The study aimed to assess if this test could reduce unnecessary antibiotics. Findings may inform future diagnostic strategies.

The study aimed to evaluate whether a rapid enzyme immunoassay test could improve prescribing decisions for sore throat. Researchers focused on reducing unnecessary antibiotic use. They compared test results to clinical assessments. The goal was to determine if the test changed physician behavior. They measured the test's sensitivity and specificity. They also tracked how often decisions were revised. The study involved general practitioners and patients. Results could guide the use of rapid tests in routine practice.

Sixty-nine general practitioners recorded prescriptions for 1,189 sore throat episodes. Researchers analyzed antibiotic use and clinical signs. An enzyme immunoassay test was introduced for 250 patients. Twenty-three practitioners participated in the test evaluation. Sensitivity and specificity were compared to clinical judgment. Researchers tracked how often test results altered decisions. Data were collected on prescribing patterns and test outcomes. The study focused on real-world clinical settings.

Antibiotics were prescribed in 64% of episodes, with 21% being broad spectrum. Clinical signs like dysphagia increased prescription rates. The enzyme test had 63% sensitivity and 91.7% specificity. Clinical assessment alone had 74% sensitivity and 58% specificity. Test results changed decisions in 13% of cases. Broad-spectrum antibiotics were less likely with test use. The test showed higher specificity but lower sensitivity. Researchers noted limited impact on overall prescribing behavior.

The enzyme immunoassay test did not significantly alter prescribing in most cases. Test results changed only 13% of decisions. Clinical assessment had higher sensitivity but lower specificity. The study suggests the test is not ready for widespread use. Authors propose further research on test accuracy. They note that current evidence does not support routine implementation. Physicians may still rely on clinical signs more heavily. The test may have a role in select cases but not broadly.